

Rosario Lopez-Pedrera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8170831/publications.pdf>

Version: 2024-02-01

151
papers

3,840
citations

117625

34
h-index

144013

57
g-index

158
all docs

158
docs citations

158
times ranked

4955
citing authors

#	ARTICLE	IF	CITATIONS
1	Thrombosis in primary antiphospholipid syndrome. A pivotal role for monocyte tissue factor expression. <i>Arthritis and Rheumatism</i> , 1997, 40, 834-841.	6.7	204
2	Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF- κ B/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK1/ERK pathway. <i>Arthritis and Rheumatism</i> , 2006, 54, 301-311.	6.7	192
3	Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNF α . <i>Arthritis Research and Therapy</i> , 2015, 17, 49.	3.5	158
4	The obese healthy paradox: is inflammation the answer?. <i>Biochemical Journal</i> , 2010, 430, 141-149.	3.7	151
5	CoCl ₂ , a Mimic of Hypoxia, Induces Formation of Polyploid Giant Cells with Stem Characteristics in Colon Cancer. <i>PLoS ONE</i> , 2014, 9, e99143.	2.5	101
6	Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1985-1992.	3.8	98
7	Nitric Oxide and Cancer: The Emerging Role of S-Nitrosylation. <i>Current Molecular Medicine</i> , 2012, 12, 50-67.	1.3	92
8	Monounsaturated Fatty Acid-Enriched Diet Decreases Plasma Plasminogen Activator Inhibitor Type 1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 82-88.	2.4	90
9	Neutrophils: Novel key players in Rheumatoid Arthritis. Current and future therapeutic targets. <i>Autoimmunity Reviews</i> , 2018, 17, 1138-1149.	5.8	88
10	Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2461-2469.	3.8	85
11	Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 675-682.	0.9	82
12	Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment. <i>Blood</i> , 2012, 119, 5859-5870.	1.4	82
13	Diagnostic potential of NETosis-derived products for disease activity, atherosclerosis and therapeutic effectiveness in Rheumatoid Arthritis patients. <i>Journal of Autoimmunity</i> , 2017, 82, 31-40.	6.5	82
14	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2021, 73, 1073-1085.	5.6	81
15	Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. <i>Translational Research</i> , 2017, 183, 87-103.	5.0	80
16	Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1441-1449.	0.9	76
17	Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies. <i>Leukemia</i> , 2006, 20, 1331-1340.	7.2	75
18	Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets. <i>Proteomics</i> , 2006, 6, S293-S299.	2.2	60

#	ARTICLE	IF	CITATIONS
19	Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1923-1932.	2.4	60
20	Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches. <i>Rheumatology</i> , 2016, 55, 2096-2108.	1.9	59
21	Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients. <i>Human Molecular Genetics</i> , 2018, 27, 875-890.	2.9	58
22	Proteomic analysis in monocytes of antiphospholipid syndrome patients: Deregulation of proteins related to the development of thrombosis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2835-2844.	6.7	55
23	Increased Dihydroceramide/Ceramide Ratio Mediated by Defective Expression of <i>degs1</i> Impairs Adipocyte Differentiation and Function. <i>Diabetes</i> , 2015, 64, 1180-1192.	0.6	55
24	Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2010, 62, 869-877.	6.7	52
25	Anticyclic Citrullinated Protein Antibodies Are Implicated in the Development of Cardiovascular Disease in Rheumatoid Arthritis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2706-2716.	2.4	52
26	Proteomic approaches to evaluate protein <i>s-nitrosylation</i> in disease. <i>Mass Spectrometry Reviews</i> , 2014, 33, 7-20.	5.4	51
27	Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1450-1458.	0.9	49
28	The role of tissue factor in the antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2001, 44, 2467-2476.	6.7	48
29	Catastrophic antiphospholipid syndrome (CAPS). <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 535-541.	3.3	44
30	Atherothrombosis-associated microRNAs in Antiphospholipid syndrome and Systemic Lupus Erythematosus patients. <i>Scientific Reports</i> , 2016, 6, 31375.	3.3	44
31	Cardiovascular Risk in Systemic Autoimmune Diseases: Epigenetic Mechanisms of Immune Regulatory Functions. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-10.	3.3	38
32	C1-esterase inhibitor prevents early pulmonary dysfunction after lung transplantation in the dog. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997, 155, 1147-1154.	5.6	37
33	Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Role of Proinflammatory Cytokines and Therapeutic Approaches. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-13.	3.0	37
34	Progression from High Insulin Resistance to Type 2 Diabetes Does Not Entail Additional Visceral Adipose Tissue Inflammation. <i>PLoS ONE</i> , 2012, 7, e48155.	2.5	36
35	Simultaneous Inhibition of EGFR/VEGFR and Cyclooxygenase-2 Targets Stemness-Related Pathways in Colorectal Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0131363.	2.5	35
36	Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. <i>Hematological Oncology</i> , 2007, 25, 30-37.	1.7	34

#	ARTICLE	IF	CITATIONS
37	Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues. <i>Journal of Internal Medicine</i> , 2018, 284, 61-77.	6.0	34
38	Distinct Patterns of Urokinase Receptor (uPAR) Expression by Leukemic Cells and Peripheral Blood Cells. <i>Thrombosis and Haemostasis</i> , 1996, 76, 1009-1019.	3.4	34
39	Antiphospholipid syndrome and tissue factor: a thrombotic couple. <i>Lupus</i> , 2006, 15, 161-166.	1.6	32
40	Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors. <i>Breast Cancer Research</i> , 2012, 14, R153.	5.0	31
41	Antithrombin III Prevents Early Pulmonary Dysfunction After Lung Transplantation in the Dog. <i>Circulation</i> , 2001, 104, 2975-2980.	1.6	30
42	VEGF targeted therapy in acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 241-256.	4.4	30
43	Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome. <i>Haematologica</i> , 2018, 103, 908-918.	3.5	30
44	VCE004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPAR γ and CB ₂ receptor-dependent pathways. <i>British Journal of Pharmacology</i> , 2018, 175, 3813-3831.	5.4	30
45	New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches. <i>Frontiers in Immunology</i> , 2019, 10, 764.	4.8	30
46	Regulation by Nitric Oxide of Endotoxin-Induced Tissue Factor and Plasminogen Activator Inhibitor-1 in Endothelial Cells. <i>Thrombosis and Haemostasis</i> , 2002, 88, 1060-1065.	3.4	29
47	Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome. <i>Rheumatology</i> , 2016, 55, 1726-1735.	1.9	29
48	Anti-dsDNA Antibodies Increase the Cardiovascular Risk in Systemic Lupus Erythematosus Promoting a Distinctive Immune and Vascular Activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2417-2430.	2.4	29
49	Antiphospholipid syndrome. <i>Clinical and Experimental Medicine</i> , 2003, 3, 129-139.	3.6	28
50	Potential Use of Statins in the Treatment of Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2012, 14, 87-94.	4.7	28
51	Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumab. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 601-610.	3.8	26
52	Identification of a Untranslated Genetic Variant of <i>RARB</i> Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 351-360.	5.6	26
53	PXK locus in systemic lupus erythematosus: fine mapping and functional analysis reveals novel susceptibility gene ABHD6. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e14-e14.	0.9	24
54	Effects of Biological Therapies on Molecular Features of Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9067.	4.1	22

#	ARTICLE	IF	CITATIONS
55	Immunotherapy in antiphospholipid syndrome. <i>International Immunopharmacology</i> , 2015, 27, 200-208.	3.8	21
56	Regulation of TFPI± expression by miR-27a/b-3p in human endothelial cells under normal conditions and in response to androgens. <i>Scientific Reports</i> , 2017, 7, 43500.	3.3	20
57	Molecular Characterization of Monocyte Subsets Reveals Specific and Distinctive Molecular Signatures Associated With Cardiovascular Disease in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2019, 10, 1111.	4.8	20
58	Role of microRNAs in the Development of Cardiovascular Disease in Systemic Autoimmune Disorders. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1212.	4.1	20
59	Impaired microRNA processing in neutrophils from rheumatoid arthritis patients confers their pathogenic profile. Modulation by biological therapies. <i>Haematologica</i> , 2020, 105, 2250-2261.	3.5	20
60	A Modulatory Role for Substance P on the Regulation of Luteinizing Hormone Secretion by Cultured Porcine Gonadotrophs1. <i>Biology of Reproduction</i> , 1998, 58, 678-685.	2.7	19
61	Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconversion?. <i>Autoimmunity Reviews</i> , 2017, 16, 1109-1114.	5.8	19
62	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021, 48, 541-547.	2.0	19
63	Pharmacological impairment of s-nitrosoglutathione or thioredoxin reductases augments protein S-Nitrosation in human hepatocarcinoma cells. <i>Anticancer Research</i> , 2010, 30, 415-21.	1.1	19
64	Enhanced NETosis generation in radiographic axial spondyloarthritis: utility as biomarker for disease activity and anti-TNF-± therapy effectiveness. <i>Journal of Biomedical Science</i> , 2020, 27, 54.	7.0	18
65	Tissue Factor (TF) and Urokinase Plasminogen Activator Receptor (uPAR) and Bleeding Complications in Leukemic Patients. <i>Thrombosis and Haemostasis</i> , 1997, 77, 062-070.	3.4	18
66	Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 56-67.	0.9	18
67	Characterization of tissue factor expression on the human endothelial cell line ECV304. , 1997, 56, 71-78.		17
68	Antiphospholipid-Mediated Thrombosis: Interplay Between Anticardiolipin Antibodies and Vascular Cells. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2006, 12, 41-45.	1.7	17
69	Therapeutic Potential and Immunomodulatory Role of Coenzyme Q10 and Its Analogues in Systemic Autoimmune Diseases. <i>Antioxidants</i> , 2021, 10, 600.	5.1	17
70	Heterogeneity of growth hormone (GH)-producing cells in aging male rats: in vitro GH releasing activity of somatotrope subpopulations. <i>Molecular and Cellular Endocrinology</i> , 1996, 123, 127-137.	3.2	16
71	To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer. <i>Current Drug Targets</i> , 2012, 13, 829-841.	2.1	16
72	Coordinated deregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute myeloid leukaemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 1187-1199.	1.3	15

#	ARTICLE	IF	CITATIONS
73	Use of povidone-iodine during the first trimester of pregnancy: a correct practice?. BJOG: an International Journal of Obstetrics and Gynaecology, 2009, 116, 452-455.	2.3	15
74	Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion. Journal of Cellular and Molecular Medicine, 2019, 23, 6308-6318.	3.6	15
75	Subclinical cardiovascular risk signs in adults with juvenile idiopathic arthritis in sustained remission. Pediatric Rheumatology, 2020, 18, 59.	2.1	14
76	Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia. Experimental Hematology, 2009, 37, 679-691.	0.4	13
77	Clinical Utility of microRNAs in Exhaled Breath Condensate as Biomarkers for Lung Cancer. Journal of Personalized Medicine, 2021, 11, 111.	2.5	13
78	Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis. Frontiers in Immunology, 2021, 12, 631662.	4.8	13
79	Promyelocytic leukemia retinoid signaling targets regulate apoptosis, tissue factor and thrombomodulin expression. Haematologica, 2004, 89, 286-95.	3.5	13
80	VEGF/KDR loop is a target of AG1296 in acute myeloid leukaemia showing FLT3 internal tandem duplications. British Journal of Haematology, 2009, 145, 836-838.	2.5	12
81	Complement component 3 as biomarker of disease activity and cardiometabolic risk factor in rheumatoid arthritis and spondyloarthritis. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232096506.	2.5	12
82	HLA-B*08 Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Anti-Carbamylated Protein Antibody-Positive/Anti-Cyclic Citrullinated Peptide-Negative Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 963-969.	5.6	12
83	Elevated levels of tissue factor pathway inhibitor in acute non-lymphoblastic leukemia patients with disseminated intravascular coagulation. Blood Coagulation and Fibrinolysis, 1997, 8, 70-71.	1.0	11
84	Characterization of Antiphospholipid Syndrome Atherothrombotic Risk by Unsupervised Integrated Transcriptomic Analyses. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 865-877.	2.4	11
85	The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast. Journal of Internal Medicine, 2022, 291, 676-693.	6.0	11
86	Novel biomarkers of atherosclerosis and cardiovascular risk in autoimmune diseases: Genomics and proteomics approaches. Proteomics - Clinical Applications, 2009, 3, 213-225.	1.6	10
87	Proteomics insights into deregulated protein S-nitrosylation and disease. Expert Review of Proteomics, 2012, 9, 59-69.	3.0	8
88	Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases. Lupus, 2008, 17, 905-916.	1.6	7
89	Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis. Therapeutic Advances in Musculoskeletal Disease, 2019, 11, 1759720X1988074.	2.7	7
90	MEK inhibition induces caspases activation, differentiation blockade and PML/RAR degradation in acute promyelocytic leukaemia. British Journal of Haematology, 2008, 142, 27-35.	2.5	6

#	ARTICLE	IF	CITATIONS
91	AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia. <i>Experimental Hematology</i> , 2010, 38, 641-652.	0.4	6
92	ES936 stimulates DNA synthesis in HeLa cells independently on NAD(P)H:quinone oxidoreductase 1 inhibition, through a mechanism involving p38 MAPK. <i>Chemico-Biological Interactions</i> , 2010, 186, 174-183.	4.0	5
93	Proteomics in antiphospholipid syndrome: a review. <i>Lupus</i> , 2010, 19, 385-388.	1.6	5
94	Circulating microRNAs as potential biomarkers for monitoring the response to in vivo treatment with Rituximab in systemic lupus erythematosus patients. <i>Autoimmunity Reviews</i> , 2020, 19, 102488.	5.8	5
95	Molecular Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs. <i>Frontiers in Immunology</i> , 2021, 12, 744022.	4.8	4
96	Plasma thrombopoietin level after liver transplantation: relationship to cold ischemia time and coagulation parameters. <i>Intensive Care Medicine</i> , 2000, 26, 804-807.	8.2	3
97	Mechanisms of atherosclerosis and cardiovascular disease in antiphospholipid syndrome and systemic lupus erythematosus. <i>New therapeutic approaches. Medicina Clínica (English Edition)</i> , 2017, 149, 160-169.	0.2	3
98	Mecanismos de aterosclerosis y enfermedad cardiovascular en el síndrome antifosfolípido y el lupus eritematoso sistémico. <i>Alternativas terapéuticas. Medicina Clínica</i> , 2017, 149, 160-169.	0.6	3
99	The effect of exogenous nitric oxide on plasminogen activator inhibitor in experimentally induced endotoxemia. <i>Fibrinolysis</i> , 1996, 10, 21-25.	0.5	2
100	THU0398...Beneficial Effects of in Vivo Ubiquinol Supplementation on Athero-Thrombosis Prevention in Antiphospholipid Syndrome Patients. Preliminary Results of a Clinical Trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 340.3-341.	0.9	2
101	Expression of DDX11 and DNM1L at the 12p11 Locus Modulates Systemic Lupus Erythematosus Susceptibility. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7624.	4.1	2
102	Patogenia de la trombosis asociada a enfermedades neoplásicas: implicaciones terapéuticas. <i>Medicina Clínica</i> , 2004, 122, 190-196.	0.6	2
103	OP0188...Circulating Mirnas as Potential Biomarkers of Therapy Effectiveness in Rheumatoid Arthritis Patients Treated with Anti-TNF. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 133.3-134.	0.9	1
104	O31...Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. , 2020, , .		1
105	Potential Role and Impact of Peripheral Blood Mononuclear Cells in Radiographic Axial Spondyloarthritis-Associated Endothelial Dysfunction. <i>Diagnostics</i> , 2021, 11, 1037.	2.6	1
106	311 INFLAMMATION, LEUKOCYTE ACTIVATION, AND SURROGATE ATHEROSCLEROSIS MARKERS IN RHEUMATOID ARTHRITIS PATIENTS ARE RELATED TO MITOCHONDRIAL DEPolarisation AND OXIDATIVE STRESS. <i>Atherosclerosis Supplements</i> , 2011, 12, 67.	1.2	0
107	414 OXIDATIVE STRESS MEDIATES APL-INDUCED THROMBOSIS AND ATHEROSCLEROSIS DEVELOPMENT IN ANTIPHOSPHOLIPID SYNDROME. <i>Atherosclerosis Supplements</i> , 2011, 12, 89.	1.2	0
108	309 Maintenance of S-nitrosothiol Homeostasis Plays an Important Role in Growth Suppression in Estrogen Receptor Positive Breast Tumors. <i>European Journal of Cancer</i> , 2012, 48, S76.	2.8	0

#	ARTICLE	IF	CITATIONS
109	713 Cyclooxygenase-2 Inhibition Enhances the Anti-tumoral Activity of the Multi-target Kinase Inhibitor AEE788 in Colorectal Cancer Cells. <i>European Journal of Cancer</i> , 2012, 48, S169.	2.8	0
110	SAT0044â€¦Anti-cyclic citrullinated protein antibodies induce inflammation and oxidative stress in monocytes and neutrophils of rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 485.3-485.	0.9	0
111	SAT0161â€¦Fluvastatin treatment prevents the inflammatory/oxidative status linked to the clinical activity of the disease in systemic lupus erythematosus patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 526.2-526.	0.9	0
112	AB0188â€¦Atherosclerosis and Cardiovascular Disease in Systemic Lupus Erythematosus. Effects of Statins Treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 865.2-865.	0.9	0
113	THU0460â€¦Charaterization of Micrnas Involved in the Regulation of Atherotrthombosis in Antiphospholipid Syndrome and Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 342.2-342.	0.9	0
114	FRI0167â€¦Effect of Infliximab and Paricalcitol on Inflammation and Mineralization/Calcification of Mesenchymal Stem Cells during Osteogenic Differentiation. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 442.2-442.	0.9	0
115	AB0133â€¦Role of Monocytes Subsets in the Atherothrombosis and Endothelial Dysfunction Associated with Rheumatoid Arthritis: Beneficial Effects of Tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 935.2-935.	0.9	0
116	FRI0190â€¦Role of Leukocyte Subsets in the Inflammation, Oxidative Stress and Bone Turnover in Ankylosing Spondylitis Patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 493.2-493.	0.9	0
117	AB0165â€¦Regulation of Atherothrombosis in Systemic Lupus Erythematosus. Role of Different Monocyte Subsets, Netosis Involvement, and Effects of Anti-Dsdna Antibodies. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 945.3-946.	0.9	0
118	OP0156â€¦In Vitro Treatment with Anti-Cardiolipin and Anti-DSDNA Antibodies Modifies the Expression of Micrnas Related to Cardiovascular Disease in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 128.1-128.	0.9	0
119	THU0243â€¦Integrated Analysis of Microna and MRNA Expression Profiles Related To Cardiovascular Disease in Monocytes from Systemic Lupus Erythematosus Patients. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 276.1-276.	0.9	0
120	THU0254â€¦In Vivo Ubiquinol (COQ10) Supplementation Reduces The Atherothrombotic Status of Antiphospholipid Syndrome Patients. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 280.1-280.	0.9	0
121	OP0310â€¦Association of Neutrophil Extracellular Traps with Atherosclerosis in Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 175.1-175.	0.9	0
122	AB0104â€¦Role of CD14+ and CD16+ Monocyte Subtypes in The Atherothrombosis Associated with Rheumatoid Arthritis: Epigenetic Mechanisms Involved. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 932.1-932.	0.9	0
123	FRI0046â€¦TCZ Attenuates Atherothrombosis through The Specific Inhibition of Netosis and Monocyte-Mediated Proinflammatory Activity. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 442.3-443.	0.9	0
124	FRI0056â€¦Altered Microna Expression Pattern in Synovial and Blood Neutrophils in Rheumatoid Arthritis Reveals The Pathogenic Profile of These Cells. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 446.1-446.	0.9	0
125	AB0124â€¦Peripheral Blood Mononuclear Cells from Ankylosing Spondylitis Patients Display An Atherogenic Profile Associated with Disease Activity and Endothelial Dysfunction. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 939.1-939.	0.9	0
126	THU0255â€¦Identification of Novel Regulatory Networks Related To Atherothrombosis in Monocytes from Antiphospholipid Syndrome through Integrated Analysis of Microna/mrna/protein Expression Profiles. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 280.2-280.	0.9	0

#	ARTICLE	IF	CITATIONS
127	FRI0429â€¦Dysregulation of the splicing machinery in leukocytes from ankylosing spondylitis patients is associated to disease pathogenesis. , 2017, , .		0
128	AB0104â€¦Alterations of spliceosome components in leukocytes from patients with rheumatoid arthritis influence their autoimmune and inflammatory profile, and the development of cardiovascular disease. , 2017, , .		0
129	AB0092â€¦Effect of methotrexate, leflunomide and hydroxychloroquine on the insulin resistance and obesity associated with rheumatoid arthritis: obese mouse models of rheumatoid arthritis. , 2017, , .		0
130	AB0127â€¦ANTI-DS-DNA antibodies regulate atherothrombosis in systemic lupus erythematosus through the induction of netosis, inflammation and endothelial activation. , 2017, , .		0
131	FRI0035â€¦Specific monocyte subsets in patients with rheumatoid arthritis are associated with the progression of the disease along with their autoimmune and pro-atherothrombotic profile. , 2017, , .		0
132	THU0218â€¦Circulating micrnas as biomarkers for diagnosis and typifying the atherothrombotic status in antiphospholipid syndrome. , 2017, , .		0
133	AB0128â€¦Alterations of the splicing machinery components in leukocytes from patients with systemic lupus erythematosus influences its development and atherothrombotic profile and drives the therapeutic response. , 2017, , .		0
134	FRI0069â€¦Neutrophils play a key role in the regulation of the chronic inflammation associated with rheumatoid arthritis through epigenetic mechanisms modulated by anti-ccps antibodies and reversed by biologic therapies. , 2017, , .		0
135	FRI0048â€¦The ANTI-CD20 antibody rituximab reduces the inflammatory and prothrombotic profile of leukocytes from rheumatoid arthritis patients and modulates the activity of endothelial cells. , 2017, , .		0
136	OP0336â€¦Role of systemic inflammation associated with rheumatoid arthritis in the glucose and lipid metabolism: humans, cia mouse model and in vitro studies. , 2017, , .		0
137	FRI0360â€¦Analysis of endocannabinoid system elements and related inflammatory molecules in peripheral blood leukocytes of patients with systemic sclerosis. , 2017, , .		0
138	FRI0431â€¦Altered expression of circulating micrnas is related to disease activity and structural damage in ankylosing spondylitis patients. , 2017, , .		0
139	AB1130â€¦Relapse risk assessment in young aps patients with previous stroke event using the adjusted global antiphospholipid syndrome score (AGAPSS). , 2017, , .		0
140	THU0225â€¦THE MOLECULAR PROFILING OF MONOCYTES FROM PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME IDENTIFIES SEVERAL NETWORKS RELATED TO THEIR ATHEROTHROMBOTIC STATUS. ROLE OF ANTIPHOSPHOLIPID ANTIBODIES ON MONOCYTE MIRNA SECRETION. , 2019, , .		0
141	AB0188â€¦MOLECULAR NETWORKS IN MONOCYTES FROM SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS RELATED TO THEIR PHYSIOPATHOLOGY. MODULATORY EFFECTS OF ANTI-DSDNA ANTIBODIES AND MOLECULAR MECHANISMS UNDERLYING IN VIVOSTATIN TREATMENT. , 2019, , .		0
142	SAT0037â€¦INCREASED CARDIOMETABOLIC RISK FACTORS ARE RELATED TO THE ABNORMAL ADIPOCYTOKINE PROFILE AND AUTOIMMUNITY IN RHEUMATOID ARTHRITIS. MODULATION BY TNFALPHA AND IL6R INHIBITORS. , 2019, , .		0
143	SAT0036â€¦IMPACT OF RHEUMATOID ARTHRITIS IN LIVER DAMAGE. INVOLVEMENT OF ANTI-CITRULLINATED PROTEIN ANTIBODIES. , 2019, , .		0
144	AB0725â€¦ASSOCIATION BETWEEN RADIOGRAPHIC PROGRESSION AND CARDIOVASCULAR RISK IN SPONDYLOARTHRITIS: DATA FROM COSPAR REGISTRY. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
145	OP0292â€¦THE HELPFUL EIGHT: KEY SPLICING MACHINERY ELEMENTS IN LEUKOCYTE SUBSETS MAY IMPROVE THE TYPIFICATION OF THE DISEASE IN RHEUMATOID ARTHRITIS PATIENTS. , 2019, , .		0
146	AB0388â€¦COMPARATIVE EFFECTIVENESS OF RITUXIMAB, TOCILIZUMAB AND TNFI BIOLOGICS IN RHEUMATOID ARTHRITIS PATIENTS. INFLUENCE OF CLINICAL AND INFLAMMATORY PROFILES. , 2019, , .		0
147	SAT0124â€¦MOLECULAR CHARACTERIZATION OF THE SERUM PROFILE ASSOCIATED TO THE INCREASED CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS PATIENTS. EFFECTS OF BIOLOGICAL DRUGS.. , 2019, , .		0
148	P92â€¦Genomic convergence of locus-based GWAS meta-analysis identifies DDX11 as a novel systemic lupus erythematosus gene. , 2020, , .		0
149	NAD+ boosters reduce the oxidative, apoptotic and inflammatory status of leukocytes from rheumatoid arthritis patients. Free Radical Biology and Medicine, 2021, 165, 36.	2.9	0
150	What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Thrombosis?. , 2012, , 57-78.		0
151	The Future Potential of Biosimilars Targeting B-Cells. Milestones in Drug Therapy, 2014, , 277-284.	0.1	0